Back to Search
KRESHNIK ZEJNULLAHU, MD
MD
Internal Medicine Physician
NPI: 1326465444IndividualAccepts Medicare
Education
UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL
Class of 2014
Research & Publications (5)
Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.
PMID 18980991·Clin Cancer Res·2008
8-other
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.
PMID 18594010·Clin Cancer Res·2008
8-other
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.
PMID 18089823·Cancer Res·2007
7-preclinical
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
PMID 17463250·Science·2007
7-preclinical
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.
PMID 16906227·J Clin Invest·2006
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Request Appointment
This provider isn't set up for online booking yet. Once you submit, we'll reach out to their office to arrange secure delivery of your request.
Contact & Hours
- Address
- 2700 GRANT ST STE 200
CONCORD, CA 94520 - Phone
- (925) 674-2609
Quick Facts
- NPI
- 1326465444
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 2
- Years in Practice
- 12
- Publications
- 5
Are you this provider?
Claim Your Profile